KIT and gastrointestinal stromal tumor: About 20–30% of all GIST are lacking KIT/PDGFRA mutations; these tumors may yield defects in the succinate dehydrogenase (SDH) complex.[16] They may respond to treatment with other RTKI than imatinib.